↓ Skip to main content

Therapeutic drug monitoring guided dosing versus standard dosing of alectinib in advanced ALK positive non-small cell lung cancer patients: Study protocol for an international, multicenter phase IV…

Overview of attention for article published in Frontiers in oncology, March 2023
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (92nd percentile)
  • High Attention Score compared to outputs of the same age and source (99th percentile)

Mentioned by

news
2 news outlets
twitter
15 X users

Readers on

mendeley
25 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Therapeutic drug monitoring guided dosing versus standard dosing of alectinib in advanced ALK positive non-small cell lung cancer patients: Study protocol for an international, multicenter phase IV randomized controlled trial (ADAPT ALEC)
Published in
Frontiers in oncology, March 2023
DOI 10.3389/fonc.2023.1136221
Pubmed ID
Authors

Marinda Meertens, M. Benthe Muntinghe-Wagenaar, Barend J. Sikkema, Marta Lopez-Yurda, Valesca P. Retèl, Marthe S. Paats, Rob Ter Heine, Ed Schuuring, Wim Timens, Daan J. Touw, Job F. M. van Boven, Adrianus. J. de Langen, Sayed M. S. Hashemi, Lizza E. L. Hendriks, Sander Croes, Michel M. van den Heuvel, Anne-Marie C. Dingemans, Ron H. J. Mathijssen, Egbert F. Smit, Alwin D. R. Huitema, Neeltje Steeghs, Anthonie J. van der Wekken

Timeline

Login to access the full chart related to this output.

If you don’t have an account, click here to discover Explorer

X Demographics

X Demographics

The data shown below were collected from the profiles of 15 X users who shared this research output. Click here to find out more about how the information was compiled.
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 25 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 25 100%

Demographic breakdown

Readers by professional status Count As %
Unspecified 6 24%
Student > Master 2 8%
Student > Bachelor 1 4%
Student > Ph. D. Student 1 4%
Unknown 15 60%
Readers by discipline Count As %
Unspecified 6 24%
Pharmacology, Toxicology and Pharmaceutical Science 1 4%
Sports and Recreations 1 4%
Immunology and Microbiology 1 4%
Medicine and Dentistry 1 4%
Other 0 0%
Unknown 15 60%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 26. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 08 July 2024.
All research outputs
#1,581,620
of 26,589,077 outputs
Outputs from Frontiers in oncology
#285
of 23,335 outputs
Outputs of similar age
#32,703
of 433,985 outputs
Outputs of similar age from Frontiers in oncology
#8
of 1,388 outputs
Altmetric has tracked 26,589,077 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 94th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 23,335 research outputs from this source. They receive a mean Attention Score of 3.2. This one has done particularly well, scoring higher than 98% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 433,985 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 92% of its contemporaries.
We're also able to compare this research output to 1,388 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 99% of its contemporaries.